Amlodipine parameters
Pro Research Analysisby 
Searched over 200M research papers for "amlodipine parameters"
Amlodipine Parameters: Pharmacokinetics, Pharmacodynamics, and Clinical Effects
Pharmacokinetics of Amlodipine
Absorption and Bioavailability
Amlodipine, a dihydropyridine calcium antagonist, exhibits a high oral bioavailability of approximately 60-65% Abernethy1989Meredith1992. After oral administration, plasma concentrations peak gradually within 6 to 8 hours . This slow absorption contributes to its prolonged therapeutic effect, making it suitable for once-daily dosing .
Distribution and Metabolism
Amlodipine has a large volume of distribution (21 L/kg) and a high degree of protein binding (98%) . It is extensively metabolized in the liver, but unlike many other drugs, it does not undergo significant presystemic or first-pass metabolism . This characteristic ensures a consistent and predictable pharmacokinetic profile.
Elimination
The drug is slowly cleared from the body, with a terminal elimination half-life ranging from 34 to 50 hours Abernethy1989Meredith1992. This extended half-life supports its once-daily dosing regimen, providing a steady therapeutic effect over 24 hours .
Pharmacodynamics of Amlodipine
Blood Pressure and Heart Rate
Amlodipine effectively reduces both systolic and diastolic blood pressure, which is beneficial for patients with hypertension . It also influences heart rate variability, reducing the influence of the sympathetic autonomic nervous system and shifting the autonomic balance towards increased vagal activity .
Metabolic Effects
Amlodipine therapy has been shown to improve several metabolic parameters. It increases HDL-cholesterol levels and plasma adiponectin while decreasing plasma leptin and resistin levels . These changes are associated with improved endothelial function and reduced oxidative stress, as indicated by lower plasma malondialdehyde levels .
Clinical Effects and Safety
Exercise Tolerance and Heart Failure
In patients with heart failure and left ventricular systolic dysfunction, amlodipine does not significantly improve exercise tolerance or quality of life compared to placebo . However, it does improve left ventricular ejection fraction, indicating a positive effect on cardiac function .
Safety Profile
Amlodipine is generally well-tolerated, with a safety profile that compares favorably to other antihypertensive agents such as beta-blockers and other calcium antagonists . The most common side effect is edema, which is usually well-tolerated . Amlodipine does not adversely affect serum creatinine, urate, fasting glucose, cholesterol, or triglyceride levels, making it a safer option for long-term use .
Gender Differences
There are slight differences in the pharmacokinetics of amlodipine between males and females, primarily due to differences in body weight. Women tend to have higher plasma concentrations of the drug, which may lead to more pronounced pharmacodynamic effects . However, these differences do not necessitate gender-specific dosing adjustments .
Conclusion
Amlodipine is a well-established antihypertensive and antianginal agent with a favorable pharmacokinetic and safety profile. Its extended half-life and high bioavailability make it suitable for once-daily dosing, ensuring consistent therapeutic effects. While it significantly improves blood pressure and metabolic parameters, its impact on exercise tolerance in heart failure patients is limited. Overall, amlodipine remains a valuable option in the management of hypertension and angina, with a well-tolerated safety profile.
Sources and full results
Most relevant research papers on this topic